Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-STAR: BHV-3241 (verdiperstat) in Multiple System Atrophy
2019-001100-38Phase 3Completed
- Sponsor
- Biohaven Ltd.
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple system atrophy (MSA) comparing BHV-3241 (verdiperstat) with Placebo (2 arms). Primary endpoint: Change from baseline in modified UMSARS at Week 48. Started Oct 2019; status: completed.
02
Drugs
verdiperstat
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on 2019-001100-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001100-38.